Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Sunday, May 13, 2018

Preliminary research shows noninvasive therapy may reverse atherosclerosis

Ask your doctor about this to see if they even have a clue about current research.
https://medicalxpress.com/news/2018-05-preliminary-noninvasive-therapy-reverse-atherosclerosis.html

An injection may one day be able to reverse atherosclerosis, according to emerging research presented at the American Heart Association's Vascular Discovery: From Genes to Medicine Scientific Sessions 2018, a premier global exchange of the latest advances in vascular biology for researchers and clinicians.
Atherosclerosis is characterized by a narrowing of arteries and blood vessels caused by a build-up of a hard, waxy substance called plaque, which is rich in cholesterol.
Drugs such as statins are used to control (LDL) the so-called bad cholesterol and thus decrease "plaque burden", explained Neel A. Mansukhani, M.D. lead author of the study and an integrated vascular surgery fellow at Northwestern University Feinberg School of Medicine in Chicago. "But statins have not been proven to reverse the disease." Mansukhani said.
Other treatment approaches for atherosclerosis, which can narrow and arteries throughout the body, include bypass surgery and stenting, but neither reverses the disease and each can cause damage to the vessel wall, he said.
"Our aim was to develop a non-invasive, non-surgical, novel therapy to halt and reverse the disease by actually targeting the with peptide-based nanofibers developed in the laboratory," Mansukhani said. The tiny fibers contained particles that helped remove cholesterol deposits from the plaque in the artery walls.
Researchers synthesized self-assembling peptide amphile nanofibers that targeted areas of plaque and could be delivered by intravenous injection. Importantly these synthetically engineered nanofibers contained an amino acid sequence that promotes the cholesterol to dissolve.
To test the concept, mice were genetically modified to rapidly develop atherosclerosis, then fed high fat diets for 14 weeks and after which the mice received biweekly injections of either the peptide amphile nanofiber or saline for 8 weeks.
"It was important that we were able to achieve reproducible results in this model in the lab, so first we wanted to confirm that the therapy actually targeted areas of atherosclerosis," Mansukhani said.
They used imaging techniques—fluorescent microscopy and pixel quantification—to determine optimum dose, concentration, binding duration and biodistribution and found they could observe the targeting effect after 24 hours, and after 48 to 72 hours the nanofiber would dissipate and it was cleared in 7 to 10 days.
After 8 weeks of treatment, plaque area in the arteries of the male mice was reduced by 11 percent and in the female mice by 9 percent.
The results "demonstrate that a novel targeted binds specifically to atherosclerotic lesions and reduces burden after a short treatment duration," Mansukhani said.
He noted, however, that this is preliminary research, and more is needed before this approach can be tested in humans.

No comments:

Post a Comment